BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $131

Benzinga Newsdesk www.benzinga.com Negative 67.9%

Neg 67.9% Neu 0% Pos 0%

BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $140 to $131.